Jivolar (Metformin Hydrochloride, Sitagliptin)

Jivolar, a fixed‑dose combination of metformin and sitagliptin, is used in the management of type 2 diabetes mellitus, a chronic metabolic disorder.

• Type 2 diabetes mellitus: improves overall glycemic control when diet, exercise, and monotherapy are insufficient.
• Inadequate response to metformin alone: adds DPP‑4 inhibition to further lower blood glucose.
• Combination therapy requirement: provides dual mechanisms to reduce hepatic glucose output and enhance insulin secretion.

• Metformin primarily decreases hepatic gluconeogenesis and increases peripheral insulin sensitivity, thereby reducing fasting glucose levels. Sitagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, prolonging the activity of incretin hormones such as GLP‑1 and GIP, which enhances glucose‑dependent insulin secretion and suppresses glucagon release. The combined effect results in complementary reductions in both basal and post‑prandial glucose concentrations. This synergy allows lower doses of each component while maintaining efficacy.

The most frequently reported adverse reactions with Jivolar involve the gastrointestinal tract and mild systemic symptoms.

Common Side Effects

• Nausea: mild to moderate feeling of sickness.
• Diarrhea: loose stools, often transient.
• Abdominal discomfort: cramping or pain in the stomach area.
• Headache: mild to moderate intensity.
• Upper respiratory tract infection: symptoms such as sore throat or runny nose.

Serious or Rare Side Effects

• Lactic acidosis: rare but life‑threatening metabolic complication.
• Severe hypoglycemia: especially when combined with insulin or sulfonylureas.
• Pancreatitis: inflammation of the pancreas presenting with abdominal pain.
• Stevens‑Johnson syndrome: severe skin reaction with blistering.
• Hepatic failure: rare liver dysfunction.

Before prescribing Jivolar, clinicians should evaluate patient-specific factors and monitor for potential risks.

• Renal function: assess eGFR and avoid use in severe renal impairment.
• Hepatic function: monitor liver enzymes in patients with existing liver disease.
• Cardiovascular status: use cautiously in patients with unstable heart failure.
• Concomitant sulfonylureas or insulin: adjust dose to reduce risk of hypoglycemia.
• Pregnancy and lactation: avoid unless benefits outweigh potential risks.
• Store at room temperature: keep in original container, protect from moisture and heat.

Jivolar may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Iodinated contrast agents: may precipitate metformin‑associated lactic acidosis; discontinue metformin before imaging.
• Insulin or sulfonylureas: combined use can cause severe hypoglycemia.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): increase sitagliptin exposure.

Moderate Interactions (Monitor Closely)

• Diuretics: may affect renal clearance of metformin.
• ACE inhibitors or ARBs: monitor renal function and potassium levels.
• Cimetidine: can raise metformin plasma concentrations.
• Rifampin: may reduce sitagliptin levels, decreasing efficacy.